(RTTNews) - While reporting financial results for the third quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) provided its adjusted earnings and sales growth guidance for the fourth quarter, and trimmed its full-year 2026 outlook.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.